Robert Jackman Dailey serves as Executive at Immune Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Robert Jackman Dailey has executed 462 insider transactions totaling $188.5K, demonstrating a bullish approach to their equity position. Their most recent transaction on Jan 15, 2016 involved purchasing 500 shares valued at $110.
Robert Jackman Dailey currently holds 22,059,859 shares of Immune Therapeutics, Inc. (IMUN), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Robert Jackman Dailey has been a net buyer of IMUN stock. They have purchased $188.5K and sold $0 worth of shares.
Robert Jackman Dailey's most recent insider trade was on Jan 15, 2016, when they purchased 500 shares at $0.22 per share.
Get notified when new Form 4 filings are submitted
| $0.21 |
| Discretionary |
| Jan 15, 2016 | IMUN | $105 | Purchase | 500 | $0.21 | Discretionary |
| Jan 15, 2016 | IMUN | $105 | Purchase | 500 | $0.21 | Discretionary |
| Jan 13, 2016 | IMUN | $190 | Purchase | 1,000 | $0.19 | Discretionary |
| Jan 12, 2016 | IMUN | $950 | Purchase | 5,000 | $0.19 | Discretionary |
| Jan 12, 2016 | IMUN | $360 | Purchase | 2,000 | $0.18 | Discretionary |
| Jan 7, 2016 | IMUN | $1.7K | Purchase | 10,025 | $0.17 | Discretionary |
| Jan 7, 2016 | IMUN | $166 | Purchase | 975 | $0.17 | Discretionary |
| Jan 5, 2016 | IMUN | $950 | Purchase | 5,000 | $0.19 | Discretionary |
| Jan 4, 2016 | IMUN | $95 | Purchase | 500 | $0.19 | Discretionary |
| Jan 4, 2016 | IMUN | $95 | Purchase | 500 | $0.19 | Discretionary |